trial

Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

NCTId NCT00237861
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment —
Sponsored by Yale University
Primary completion 2002-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
—
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
—
Primary completion
2002-12
Eligibility
ALL

Interventions & indications

Drugs
RisperidoneOlanzapineQuetiapine

Sponsors

Yale UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Scott W. Woods, MDPrincipal Investigator

Sites

0 total

Facts & assertions

3 sourced
Phase
PHASE4
Primary Completion Date
2002-12
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Olanzapine
drug
Quetiapine
drug
lead_sponsor
Yale University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Scott W. Woods, MD
person